Matthew Gline sold $38M of ROIV
CEO at Roivant Sciences Ltd.. 1,740,000 shares at an average of $21.68, traded Dec 15, 2025, filed Dec 17, 2025.
Score components
- +25RoleCEO
- +25Trade size$37.7M at market
- 0Share of holdings soldSold 9.9% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +1.9%, 3m +22.5%, 6m +37.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-25-045906, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2025 | MOption exercise Common Shares | +234,096 | $4.06 | $950k | 17,521,177 | Dec 17, 2025 |
| Dec 15, 2025 | SOpen-market sale Common Shares | -230,357 | $21.68 | $5.0M | 17,290,820 | Dec 17, 2025 |
| Dec 15, 2025 | JOther Common Shares | -3,739 | $21.68 | $81k | 17,287,081 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Common Shares | +1,363,711 | $12.68 | $17M | 18,650,792 | Dec 17, 2025 |
| Dec 15, 2025 | SOpen-market sale Common Shares | -566,116 | $21.68 | $12M | 18,084,676 | Dec 17, 2025 |
| Dec 15, 2025 | JOther Common Shares | -797,595 | $21.68 | $17M | 17,287,081 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Common Shares | +2,272,852 | $12.68 | $29M | 19,559,933 | Dec 17, 2025 |
| Dec 15, 2025 | SOpen-market sale Common Shares | -943,527 | $21.68 | $20M | 18,616,406 | Dec 17, 2025 |
| Dec 15, 2025 | JOther Common Shares | -1,329,325 | $21.68 | $29M | 17,287,081 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -234,096 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -1,363,711 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -2,272,852 | $0.00 | $0 | 0 | Dec 17, 2025 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 35Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 38Weak | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $12M 335,174 shares | -2% | |
| 38Weak | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $24M 664,826 shares | -4% | |
| 20Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.0M 200,000 shares | -11% | |
| 15Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $349k 10,000 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.